UNICREDIT BANK/CALL/ASTRAZENECA/13000/0.1/18.12.24 | Market Closed - BOERSE MUENCHEN 01:16:19 18/05/2024 am IST | ||
| 0.73 EUR | -2.67% |
|
| 1 month | +102.78% | ||
| 3 months | +329.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.73 | -2.67% |
| 16/24/16 | 0.75 | -5.06% |
| 15/24/15 | 0.79 | -5.95% |
| 14/24/14 | 0.84 | -2.33% |
| 13/24/13 | 0.86 | -5.49% |
Real-time BOERSE MUENCHEN
Last update May 18, 2024 at 01:16 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HC8N2C |
| ISIN | DE000HC8N2C4 |
| Date issued | 14/08/2023 |
| Strike | 13,000 p |
| Maturity | 18/12/2024 (215 Days) |
| Parity | 10 : 1 |
| Emission price | 0.79 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.94 € |
|---|---|
| Lowest since issue | 0.11 € |
| Spread | 0.03 € |
| Spread % | 4.05% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.6
USD
Spread / Average Target
+8.90%
- Stock Market
- Warrants
- Warrant
